I am aware the love for Novel Oral Anticoagulants (NOACs) is growing and that warfarin is falling out of favour, especially in the setting of stroke prevention in atrial fibrillation or in the management of venous thromboembolism. But hear me out on this one. Warfarin should stay and here’s why.
This year for Hypertension Awareness Month and World Hypertension Day (May 17), I want to discuss about the role of single pill combination in the management of hypertension. Single Pill Combination has been consistently recommended in various Hypertension Guidelines to assist with blood pressure control. However, there is no great resource to guide available options of single pill combination in Ontario.
As we begin the dialogue this week on mental health awareness week, I also want to highlight some useful resources for pharmacists. Here are few of my favourites:
A patient was presented at the ER with an unprovoked deep vein thrombosis (DVT). It was eventually assessed to require indefinite oral anticoagulation therapy. He was started on rivaroxaban, a NOAC (novel oral anticoagulant). Rivaroxaban as well as other NOACs are recommended in the latest Chest guidelines as first line treatment options for venous thromboembolism disease. But the provincial drug plan does not recognize this update yet and is set up such that warfarin is the preferred agent for long term anticoagulation therapy. NOACs would only be reimbursed for the initial 6 months if treating conditions such as DVT.
From Apr 21 to 28, it’s National Immunization Awareness Week in Canada. So I think it is timely to share this story on immunization record. I have received few “threatening” letters from Public Health that my daughter would soon be expelled from school because her immunization records were incomplete.
I recently blogged about the drug shortage of Nabilone which I thought has resolved. So when I heard patients having difficulty with getting the medication again, I picked up the phone and started calling.